Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Folic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.72 |
| ▸ | TYMS known ✓ | P04818 | 2/20 | 0.72 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.72 |
| ▸ | DHFR known ✓ | P00374 | 9/20 | 0.66 |
| ▸ | GART known ✓ | P22102 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | TLR4 | O00206 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folic Acid SCHEMBL10390873 | 1.00 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL28340014 | 1.00 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL28276635 | 0.99 | KDM4E (0.71) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL12148554 | 0.99 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL3878 | 0.99 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL6470174 | 0.99 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL29677832 | 0.99 | KDM4E (0.73) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL23388805 | 0.98 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL1887022 | 0.98 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB | |
| Folic Acid SCHEMBL652283 | 0.98 | KDM4E (0.72) | KDM4EMEN1ALDH1A1TYMSPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119286722-A | Coli culture medium and application thereof in preparation of cell extract required for cell-free protein synthesis | 江苏百时美生物科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-2026769-B1 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS | FERRER INT (ES) | 2010-03-17 | — | — | EP | claimed |
| US-20090196922-A1 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS | FERRER INTERNACIONAL, S.A. (ES) | 2009-08-06 | — | — | US | claimed |
| CN-101453992-A | Bilayer tablet for preventing cardiovascular events | FERRER INT (ES) | 2009-06-10 | — | — | CN | claimed |
| EP-2026769-A1 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS | FERRER INTERNACIONAL, S.A. (ES) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134870-A1 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS | FERRER INTERNACIONAL, S.A. (ES) | 2007-11-29 | — | — | WO | claimed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| CN-119286722-A | Coli culture medium and application thereof in preparation of cell extract required for cell-free protein synthesis | 江苏百时美生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-2753702-B1 | CELL-FREE PREPARATION OF CARBAPENEMS | GREENLIGHT BIOSCIENCES INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-4206307-A | SODIUM BOROHYDRIDE, NUETRALIZATION, ASCORBID ACID AS ANTIOXIDANT | UNITED STATES OF AMERICA (US) | 1980-06-03 | — | — | US | disclosed |
| US-4148999-A | 5-FORMYL-TETRAHYDROFOLIC ACID | THE GOVERNMENT OF THE UNITED STATES OF AMERICA (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | MEN1 605/4885TYMS 3090/4885PTGS2 4269/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | MEN1 605/4885TYMS 3090/4885PTGS2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.